CUE Market Analysis
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-4.530.0% YoY
Profit margin-59.7%HEALTHCARE
Market cap$112.7MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 5.24
- P/S (TTM)
- 3.44
- EV/EBITDA
- -1.76
Profitability & growth
- ROE (TTM)
- -138.5%
- Operating margin
- -94.3%
- Revenue growth YoY
- 1251.0%
- Dividend yield
- —
- Beta
- 2.46
Last earnings
May 14, 2026 · Estimate $-3.30 · Reported $-1.08
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Cue Biopharma
Company profileCue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 40 GUEST STREET, BOSTON, MA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$112.7M
Shares outstanding$4.2M
52W high$45.50
52W low$4.97
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent